P16.04 CDK4/6 Inhibitors Reverse Resistance to Anti-PD-1 Therapy in Lung Adenocarcinoma with LKB1 Deficiency Through pRB-ICAM1 Dependent Signaling

LKB1 deficiency is reported to lead to primary resistance to immune checkpoint inhibitors (ICIs) in lung adenocarcinoma. But specific molecular mechanism behind it is still incompletely understood and probably is the breakthrough to reshape microenvironment and restore anti-tumor immunity.